Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Feb:27:20-26.
doi: 10.1016/j.tmaid.2019.01.008. Epub 2019 Jan 14.

The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review

Kristin L Andrejko  1 , Romana C Mayer  2 , Stephanie Kovacs  3 , Emma Slutsker  4 , Emily Bartlett  5 , Kathrine R Tan  6 , Julie R Gutman  7
Affiliations

The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review

Kristin L Andrejko et al. Travel Med Infect Dis. 2019 Jan-Feb.

Abstract

Background: Malaria infection poses a significant risk in pregnancy, yet chemoprophylaxis for pregnant women is limited. A systematic review was conducted to evaluate the incidence of adverse outcomes after atovaquone-proguanil (AP) exposure during pregnancy.

Methods: Following PRISMA guidelines, the authors searched PubMed, MEDLINE, and the Malaria in Pregnancy Consortium Library to identify relevant literature including infant outcomes after exposure to atovaquone, proguanil, or AP in pregnancy. Two authors independently screened the titles, abstracts, and full texts, and extracted data into an EpiInfo database. Overall proportions and 95% confidence intervals of adverse outcomes were determined by pooling data across studies.

Results: Of 455 records identified, 16 studies were included: ten AP studies and six proguanil studies. The overall proportions and 95% confidence intervals (CI) of adverse outcomes reported for the 446 women exposed to AP include miscarriage (8.08% CI: 5.07, 12.08%), stillbirth (1.05% CI: 0.03, 5.73%), early neonatal death (0% CI: 0, 7.4%), and congenital anomalies (2.56% CI: 1.28, 4.53%).

Conclusions: The limited available data suggest that outcomes following AP exposure during pregnancy are similar to expected rates in similar populations. AP may be a promising option for pregnant women, but further data are needed on its safety in pregnancy.

Keywords: Antimalarials; Chemoprophylaxis; Female; Humans; Infant; Newborns; Plasmodium; Pregnancy.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
PRISMA diagram.
Fig. 2.
Fig. 2.
a. Congenital anomalies. b. Death. c. Stillbirth. d. Miscarriage.
See this image and copyright information in PMC

References

    1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93–104. 10.1016/S1473-3099(07)70021-X. - DOI - PubMed
    1. Pasternak B, Hviid A. Atovaquone-proguanil use in early pregnancy and the risk of birth defects. Arch Intern Med 2011;171:259–60. 10.1001/archinternmed.2010.521. - DOI - PubMed
    1. Pregnant Travelers - Chapter 8 – 2018 Yellow Book | Travelers’ Health | CDC n.d. https://wwwnc.cdc.gov/travel/yellowbook/2018/advising-travelers-with-spe... (accessed July 23, 2018).
    1. Tan KR, Magill AJ, Parise ME, Arguin PM. Centers for Disease Control and Prevention. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg 2011;84:517–31. 10.4269/ajtmh.2011.10-0285. - DOI - PMC - PubMed
    1. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75:402–15. - PubMed

Publication types

MeSH terms